Market Overview

Clovis Oncology CO-1686 Clinical Data Accepted as Oral Presentation at 2014 ELCC


Clovis Oncology (NASDAQ: CLVS) announced today that an abstract
discussing the findings of the ongoing Phase I portion of the Phase I/II
clinical study of CO-1686 has been accepted for Proffered Paper (Oral)
presentation during the 4th European Lung Cancer Conference
(ELCC). CO-1686 is the Company's novel, oral, targeted covalent
(irreversible) inhibitor of mutant forms of the epidermal growth factor
receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC)
in patients with initial activating EGFR mutations as well as the
dominant resistance mutation T790M. The conference takes place March
26-29, 2014 in Geneva, Switzerland.

See full press release

Posted-In: News Guidance Management Global


Related Articles (CLVS)

View Comments and Join the Discussion!